Deborah Heart and Lung Center announces its successful hospital-wide go live with Ivenix, a modern smart infusion pump system.
“Though everyone is familiar with IV pump delivery systems used to administer medications during a patient’s hospital stay, improvements in technology have
allowed us to do it in a controlled and measured way,” said Rita Zenna, RN, Deborah’s Vice President for Patient Care Services. “This is why we replaced our existing pumps with Ivenix, a state-of-the-art infusion system capable of measuring and controlling medication delivery.”
“Our staff is thrilled with how easy the new pumps are to work with and the enhanced capabilities that are offered,” added Sue Campano, Deborah’s Vice President for Support Services. “Our nurses collaborated extensively when evaluating our choices and ultimately selected Ivenix, a solution they believed would best meet their ability to care for patients.”
“We are enthusiastic about the opportunity to partner with Deborah Heart and Lung Center and bring this innovative infusion system to more clinicians and patients,” said Susan Niemeier, Chief Nursing Officer of Ivenix. “Advancing medication safety and clinical outcomes is critical for a hospital, and we’re honored to support Deborah Heart’s efforts to protect patient health.”
The Ivenix Infusion System includes a large-volume infusion pump, portfolio of administration sets, and infusion management software with unique capabilities for infusion therapy market. Its adaptive fluid delivery reduces flow and accuracy variability to help improve patient safety. Its patient-centered design benefits patients because clinicians spend less time troubleshooting pumps or resolving nuisance alarms, which simplifies infusion delivery for those providing bedside care. Additionally, the Ivenix System can seamlessly integrate with Deborah Heart’s electronic medical record and other hospital information systems, further reducing the possibility of patient medication errors.
“We are excited about how the system is designed to prevent medication errors, reduce nuisance alarms and other common interruptions,” said Zenna. “This will have a significant impact on our ability to provide high-quality care and ensure our patients get the rest needed after surgery.” She added, “We continue to invest in smart technology, and this was a natural next step for us. Our clinical teams are pleased with how smoothly the system was rolled out across the entire hospital.”
About Deborah Heart and Lung Center
Deborah Heart and Lung Center in Browns Mills, NJ is an 89-bed teaching hospital that specializes in the prevention, diagnosis, research, and treatment of heart, lung, and vascular diseases. Founded in 1922, Deborah has been a regional and nationally recognized leader throughout its 100-year history, during which time it has healed 2.3 million patients from every corner of the United States and 87 countries in the world. From performing the first open heart surgeries (adult and pediatric) in New Jersey, to running one of the highest volume left-ventricular assist device (LVAD) implant programs in the region, Deborah has stood at the forefront of medical innovation, all while never wavering from its founding mission “there is no price on life.” Deborah is consistently recognized as a leader in patient care from the Centers for Medicare and Medicaid Services, ranked among the top hospitals in New Jersey for patient satisfaction; holds a top-tier Society of Thoracic Surgeons rating which places Deborah among the best cardiac surgery programs in the country; and is designated a national Top Teaching Hospital by The Leapfrog Group. Deborah is an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute.
About Ivenix, Inc.
Ivenix, located in North Andover, Mass., is a medical technology company with the vision of eliminating infusion-related errors by transforming infusion delivery. The Ivenix Infusion System includes a large-volume infusion pump, a portfolio of administration sets, and a suite of infusion management tools and analytics to inform care and advance clinical and operational efficiency. Infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the US Food and Drug Administration (FDA). Infusion-related adverse drug events account for more than $2 billion in annual healthcare costs. Ivenix has a vision and commitment to improving infusion safety and medication delivery. Visit ivenix.com or connect on Twitter, Facebook, and LinkedIn.